NCT00240032View on ClinicalTrials.gov

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

July 31, 2006

Conditions
Multiple Sclerosis
Interventions
DRUG

glatiramer acetate injection with oral cetirizine hydrochloride

Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet

DRUG

glatiramer acetate with placebo

Copaxone® injection 20 mg, oral placebo

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00240032 - A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®. | Biotech Hunter | Biotech Hunter